-+ 0.00%
-+ 0.00%
-+ 0.00%

Cabaletta Bio signs 10-year rese-cel commercial supply deal with Cellares

PUBT·04/28/2026 12:07:02
Listen to the news
Cabaletta Bio signs 10-year rese-cel commercial supply deal with Cellares
  • Cabaletta Bio signed 10-year commercial supply agreement with Cellares for automated manufacturing of investigational CAR T therapy rese-cel.
  • Deal targets commercial-scale capacity for thousands of rese-cel batches per year, pending FDA approval.
  • Cellares platforms are expected to support lower cost per batch versus conventional CDMO manufacturing.
  • Agreement follows first two rese-cel doses produced on Cellares Cell Shuttle meeting release specifications in Cabaletta RESET clinical program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604280800BIZWIRE_USPR_____20260428_BW853142) on April 28, 2026, and is solely responsible for the information contained therein.